Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pneumo 23** is a Sanofi 23-valent pneumococcal capsular polysaccharide vaccine for active immunization against disease caused by the *Streptococcus pneumoniae* serotypes represented in the product. It contains purified capsular polysaccharides from 23 pneumococcal serotypes and induces serotype-specific anti-capsular antibody responses that support opsonization and immune clearance of pneumococci. It is a non-conjugated polysaccharide vaccine, not a pneumococcal conjugate vaccine, and is used to help prevent pneumococcal infections, including invasive disease and pneumococcal pneumonia, in individuals aged 2 years and older for whom vaccination is indicated. ([registrasiobat.pom.go.id](https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Pneumo23.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pneumo 23.